FDA Limits Use of Johnson and Johnson Vaccine Due to Blood Clots

The FDA has limited the use of the Johnson and Johnson COVID vaccine to only those over 18-years-old due to blood clotting issues. [Press Release Here] Johnson & Johnson’s Covid-19 vaccine is now limited to adults due to the risk of a rare blood clotting syndrome.

FDA – “Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.” (read more)

WHAT CHANGED? – “The FDA and CDC have continuously monitored for and investigated all suspected cases of TTS reported to VAERS. In an updated analysis of TTS cases following administration of the Janssen COVID-19 Vaccine that were reported to VAERS through March 18, 2022, the FDA and CDC have identified 60 confirmed cases, including nine fatal cases. The FDA has determined that the reporting rate of TTS is 3.23 per million doses of vaccine administered and the reporting rate of TTS deaths is 0.48 per million doses of vaccine administered.”